$CBMG News

Last published 3y ago

3y agoCBMGC-CAR066 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL) - NCT05784441ClinicalTrials.govCalculate the incidence of adverse events, Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 dose (RP2D), Determine the overall response rate (ORR), (and 3 more...)
3y agoCBMGC-TIL051 in Non-Small Cell Lung Cancer - NCT05676749ClinicalTrials.govCalculate the Incidence of Adverse Events or Dose Limiting Toxicities, Calculate Objective Response Rate (ORR) of all Subjects, Calculate Duration of Response (DOR) of All Subjects, (and 2 more...)
3y agoCBMGASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) - NCT05632380ClinicalTrials.govIncidence rate and severity of adverse events (AE), Progression free survival (PFS), MRD negativity rate, (and 8 more...)
4y agoCBMGA Phase Ib/II Study of C-CAR088 in Patients With Relapsed or Refractory Multiple Myeloma - NCT05521802ClinicalTrials.gov[phase Ib] Incidence and severity of Adverse Events, [phase II] Overall response rate (ORR) at 3 months after C-CAR088 infusion, Overall response rate (ORR), (and 15 more...)
4y agoCBMGA Phase I Study of C-TIL052A Cell Therapy in Advanced Cervical Cancer - NCT05475847ClinicalTrials.govSafety and tolerability of C-TIL052A cell therapy, Objective Response Rate (ORR), Disease Control Rate (DCR), (and 4 more...)
4y agoCBMGA Study of C-CAR039 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - NCT05421663ClinicalTrials.govIncidence of Adverse Events [Safety and Tolerability], The recommended Phase 2 dose (RP2D) of C-CAR039 in patients with r/r B-NHL, Overall response rate (ORR), (and 7 more...)
5y agoCBMGA Study on the Immune-response to COVID-19 Vaccination in Cancer Patients - the IOSI-COVID-19-001 Study - NCT04800146ClinicalTrials.govImmune response to SARS-CoV-2 vaccine in cancer patients, changes in serum antibodies anti SARS-CoV-2 after vaccination, Cellular immune response to SARS-CoV-2 vaccine, Immune response to SARS-CoV-2 vaccine according tumor and treatment type
5y agoCBMGCellular Biomedicine Group, Inc. Announces Completion of MergerPR NewswireCellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") today announced the completion of the merger (the "Merger") of the Company...
5y agoCBMGCellular Biomedicine Group, Inc. Stockholders Approve MergerPR NewswireCellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company's special meeting of stockholders held...
5y agoCBMGLeading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed MergerPR NewswireCellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of...
5y agoTNAV CLCT ARA CBMGMoore Kuehn Encourages CBMG, CLCT, TNAV, and ARA Investors to Contact Law FirmGlobeNewswireNEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...
5y agoCBMGRigrodsky & Long, P.A. Reminds Investors of Investigation of Cellular Biomedicine Group, Inc. BuyoutGlobeNewswireWILMINGTON, Del., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Cellular Biomedicine Group, Inc. (“CBMG”) (NASDAQ GS: CBMG) regarding possible...
5y agoCBMGCellular Biomedicine Group Announces Data to be Presented at 2020 ASH Annual MeetingPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
6y agoCXO CGIX CBMG RESIMoore Kuehn Encourages CGIX, CXO, CBMG, and RESI Investors to Contact Law FirmGlobeNewswireNEW YORK, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...
6y agoCBMGCellular Biomedicine Group Reports Q3 2020 Financial Results and Business HighlightsPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
6y agoCBMGWolf Popper LLP Investigates the Proposed Acquisition of Cellular Biomedicine Group, Inc. by a Controlling Shareholder ConsortiumPR NewswireWolf Popper LLP is investigating claims on behalf of investors in Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning the proposed acquisition ...
6y agoBDGE CGIX CBMG BMCHMoore Kuehn Encourages BDGE, CBMG, CGIX, and BMCH Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 24, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
6y agoCBMGA Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of Pulmonary Infection - NCT04544215ClinicalTrials.govPrimary Outcome Measures:, 1.Bacterial clearance rate on the 8th d;, 2.Mortality on the 28th and 90th d;, (and 5 more...)
6y agoCBMGCellular Biomedicine Group to Present at Chinese Biopharmaceutical Association-USA Annual ConferencePR NewswireCellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of...
6y agoMJCO CBMG INWKMoore Kuehn Encourages MJCO, CBMG, SCBH, and INWK to Contact Law FirmPR NewswireMoore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
6y agoCBMGCellular Biomedicine Group (CBMG) Reports Q2, H1 2020 Financial Results and Business HighlightsPR NewswireCellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of...
6y agoCBMGCellular Biomedicine Group (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going PrivatePR NewswireCellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of...
6y agoCBMGCellular Biomedicine Group (CBMG) Hosts R&D Showcase and Provides Updates to Clinical ProgramsPR NewswireCellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of...
6y agoCBMGCellular Biomedicine Group (CBMG) to Host Investor R&D Showcase Highlighting Updates to Clinical ProgramsPR NewswireCellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of...
6y agoCBMGCellular Biomedicine Group (CBMG) Announces Results of 2020 Annual Meeting of StockholdersPR NewswireCellular Biomedicine Group Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
6y agoCBMGCellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting AFP-Positive Liver Cancer at AACR Annual MeetingPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
6y agoCBMGNew patent application published for: Cell Cryopreservation Formulation and Cell Recovery MethodUS Patent Applications (USPTO)( 1 of 1 )
6y agoCBMGCellular Biomedicine Group (CBMG) Announces 2020 Annual Meeting of StockholdersPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
6y agoCYRX CYRXW CBMGCryoport Revenue Grows 47% for First Quarter 2020PR NewswireCryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), a global leader in life sciences solutions, today announced financial results for the...
6y agoCBMGCellular Biomedicine Group Reports Q1 2020 Financial Results and Business HighlightsPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
6y agoCBMGCellular Biomedicine Group to Report First Quarter 2020 Results on May 6, 2020PR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
6y agoCBMGCellular Biomedicine Group's (CBMG) CEO Tony Liu on Q4 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
6y agoCBMGCellular Biomedicine Group Announces Q4 and Full Year 2019 Financial Results and Recent Operational ProgressPR NewswireCellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of...
6y agoCBMGWhy Markets Are Underpricing Geopolitical RiskBloomberg
6y agoCBMGCellular Biomedicine Group Announces Engagement of Independent Advisors by Special CommitteePR NewswireCellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG") today announced that the special committee of its board of directors, composed of Alan Au,...
6y agoCBMGCellular Biomedicine Group Presents First Clinical Data of IIT Phase 1 Trial of C-CAR088, a Novel BCMA CAR-T, at the 61st Annual Meeting of the American Society of HematologyPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group Announces Receipt of a Preliminary Non-Binding "Going Private" ProposalPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group Reports Third Quarter of 2019 Financial Results and Business HighlightsPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group to Report Third Quarter 2019 Results on November 6, 2019PR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group Announces New Facility to Expand Research and Development and to Support Clinical DevelopmentPR NewswireCellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of...
7y agoCBMGCellular Biomedicine Group to Present at the 2019 Cantor Global Healthcare ConferencePR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group's ReJoin® Therapy Receives Stem Cell Drug Application Acceptance For Phase II Clinical Trials by China NMPAPR NewswireCellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the development of immunotherapies for ...
7y agoCBMGCellular Biomedicine Group Hosts Meeting with Investigators to Launch AlloJoin® Knee Osteoarthritis Phase II Clinical TrialPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group to Present at 5th Annual CAR-TCR Summit in BostonPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group to Present at Baird's 2019 Global Healthcare ConferencePR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group, Inc. (CBMG) CEO Bizuo Liu on Q2 2019 Results - Earnings Call TranscriptEarnings Call Transcripts
7y agoCBMGCellular Biomedicine Group Reports Second Quarter and First Half of 2019 Financial Results and Business HighlightsPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group to Report Second Quarter 2019 Results on August 6, 2019PR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group Executives to Present at CAR-TCR Summit AsiaPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...
7y agoCBMGCellular Biomedicine Group Announces First Patient Dosing in Phase I Clinical Trial of Anti-CD20 CAR-T for Lymphoma in ChinaPR NewswireCellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies ...